Clinical Trial Update: Efficacy of Rituximab in Acute Cellular Rejection in Renal Transplant Patients [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating rituximab for acute cellular rejection in renal transplant patients was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cellular Rejection
• Renal Transplant Rejection

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Hannover Medical School | Conditions: Acute Rejection | Phase 3 | Status: TERMINATED